1. Home
  2. RFL vs CELU Comparison

RFL vs CELU Comparison

Compare RFL & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rafael Holdings Inc. Class B

RFL

Rafael Holdings Inc. Class B

HOLD

Current Price

$1.31

Market Cap

61.1M

Sector

Finance

ML Signal

HOLD

Logo Celularity Inc.

CELU

Celularity Inc.

HOLD

Current Price

$1.24

Market Cap

35.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RFL
CELU
Founded
2017
2016
Country
United States
United States
Employees
N/A
123
Industry
Real Estate
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
61.1M
35.2M
IPO Year
2017
N/A

Fundamental Metrics

Financial Performance
Metric
RFL
CELU
Price
$1.31
$1.24
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$6.00
AVG Volume (30 Days)
103.5K
104.5K
Earning Date
03-30-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
28.28
N/A
EPS
N/A
N/A
Revenue
$917,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$76.00
P/E Ratio
N/A
N/A
Revenue Growth
43.96
N/A
52 Week Low
$1.12
$1.01
52 Week High
$3.19
$4.35

Technical Indicators

Market Signals
Indicator
RFL
CELU
Relative Strength Index (RSI) 52.39 48.66
Support Level $1.35 $1.21
Resistance Level $1.38 $1.33
Average True Range (ATR) 0.12 0.11
MACD -0.01 0.00
Stochastic Oscillator 32.73 49.99

Price Performance

Historical Comparison
RFL
CELU

About RFL Rafael Holdings Inc. Class B

Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.

About CELU Celularity Inc.

Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.

Share on Social Networks: